

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<p>In re Application of T. Shantha Raju Serial No.: 09/183,824</p>	<p>Group Art Unit: 1634 Examiner: To Be Assigned</p>
<p>Filed: 30 October 1998 For: METHODS AND COMPOSITIONS COMPRISING GLYCOPROTEIN GLYCOFORMS</p>	<p>CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on February 1, 1999 <i>Janet Tse</i> Janet Tse</p>

RECEIVED

INFORMATION DISCLOSURE STATEMENT

FEB 5 1999

Assistant Commissioner of Patents
Washington, D.C. 20231

MATRIX CUSTOMER
SERVICE CENTER

Sir:

In accordance with the duty imposed by 37 CFR §1.56 to disclose to the Patent Office information coming to the attention of each individual associated with the filing or prosecution of the subject application which may be material to the patentability of any claim of the application, Applicants direct the Examiner's attention to the information listed on the attached Form 1449 (Modified). A copy of the items on the PTO-1449 (Modified) is supplied herewith.

This Information Disclosure Statement is filed within three months after the filing date of the application or within three months after the date of entry of the national stage of a PCT application as set forth in 37 CFR§1.491.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is

"prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,

GENENTECH, INC.

Date: 1 February 1999

By: 

Jeffrey S. Kubinec

Reg. No. 36,575

1 DNA Way
So. San Francisco, CA 94080-4990
Phone: (650) 225-8228
Fax: (650) 952-9881